Presse medicale (Paris, France : 1983) · 2020
ANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission induction and maintenance.
СтатьяКлинические рекомендацииОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Terrier Benjamin, Charles Pierre, Aumaître Olivier, Belot Alexandre, Bonnotte Bernard, Crabol Yoann, Durel Cécile-Audrey, Ebbo Mikael, Jourde-Chiche Noémie, Lega Jean-Christophe, Puéchal Xavier, Pugnet Grégory, Quemeneur Thomas, Ribi Camillo, Samson Maxime, Vandergheynst Frédéric, Guillevin Loïc, French Vasculitis Study Group
Аннотация
Treatment of vasculitides associated with anti-neutrophil cytoplasm antibodies (ANCA) (AAVs) has evolved dramatically in recent years, particularly since the demonstration of rituximab efficacy as remission induction and maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. In 2013, the French Vasculitis Study Group (FVSG) published recommendations for its use by clinicians. Since then, new data have made it possible to better specify and codify prescription of rituximab to treat AAVs. Herein, the FVSG Recommendations Committee, an expert panel comprised of physicians with extensive experience in the treatment and management of vasculitides, presents its consensus guidelines based on literature analysis, the results of prospective therapeutic trials and personal experience.